JP7609798B2 - Ｐｒｍｔ５インヒビター及びその使用 - Google Patents

Ｐｒｍｔ５インヒビター及びその使用 Download PDF

Info

Publication number
JP7609798B2
JP7609798B2 JP2021557342A JP2021557342A JP7609798B2 JP 7609798 B2 JP7609798 B2 JP 7609798B2 JP 2021557342 A JP2021557342 A JP 2021557342A JP 2021557342 A JP2021557342 A JP 2021557342A JP 7609798 B2 JP7609798 B2 JP 7609798B2
Authority
JP
Japan
Prior art keywords
compound
cancer
pharma
alkyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021557342A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521818A5 (enExample
JP2022521818A (ja
Inventor
オーボイル，ブレンダン，エム．
リーブス，コリー，エム．
ヒルフ，ジャスティン，エー．
ストルツ，ブライアン，エム．
バートバーガー，マイケル，ディー．
ウィッテンバーガー，スティーブン，ジェイ．
ローソン，オリバー，シー．
マクダーモット，マルティナ，エス．
オーブライアン，ニール，エー．
スレイモン，デニス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2022521818A publication Critical patent/JP2022521818A/ja
Publication of JP2022521818A5 publication Critical patent/JP2022521818A5/ja
Application granted granted Critical
Publication of JP7609798B2 publication Critical patent/JP7609798B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2021557342A 2019-03-25 2020-03-25 Ｐｒｍｔ５インヒビター及びその使用 Active JP7609798B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962823374P 2019-03-25 2019-03-25
US62/823,374 2019-03-25
US201962874773P 2019-07-16 2019-07-16
US62/874,773 2019-07-16
PCT/US2020/024654 WO2020198323A1 (en) 2019-03-25 2020-03-25 Prmt5 inhibitors and uses thereof

Publications (3)

Publication Number Publication Date
JP2022521818A JP2022521818A (ja) 2022-04-12
JP2022521818A5 JP2022521818A5 (enExample) 2023-04-03
JP7609798B2 true JP7609798B2 (ja) 2025-01-07

Family

ID=72609147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557342A Active JP7609798B2 (ja) 2019-03-25 2020-03-25 Ｐｒｍｔ５インヒビター及びその使用

Country Status (12)

Country Link
US (1) US12583859B2 (enExample)
EP (1) EP3947387B1 (enExample)
JP (1) JP7609798B2 (enExample)
KR (1) KR20220023330A (enExample)
CN (1) CN114127072B (enExample)
AU (1) AU2020245480A1 (enExample)
BR (1) BR112021019125A2 (enExample)
CA (1) CA3134779A1 (enExample)
IL (2) IL318073A (enExample)
MX (1) MX2021011524A (enExample)
SG (1) SG11202110272SA (enExample)
WO (1) WO2020198323A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
IL318073A (en) 2019-03-25 2025-02-01 California Inst Of Techn PRMT5 inhibitors and their uses
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
WO2022026892A1 (en) 2020-07-31 2022-02-03 Tango Therapeutics, Inc. Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers
CN117157297A (zh) * 2021-07-20 2023-12-01 上海齐鲁制药研究中心有限公司 Prmt5抑制剂
EP4458836A4 (en) * 2021-12-27 2025-05-21 Riken Genesis Co., Ltd. Novel artificial nucleic acid, method for producing same, and use of same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018065365A1 (en) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
WO2018160824A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
JP2018528946A (ja) 2015-08-26 2018-10-04 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤として使用するための新規な６−６二環式芳香環置換ヌクレオシド類似体
WO2019110734A1 (en) 2017-12-08 2019-06-13 Janssen Pharmaceutica Nv Novel spirobicyclic analogues

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
KR102028793B1 (ko) 2013-03-14 2019-10-07 에피자임, 인코포레이티드 아르기닌 메틸기 전이효소 억제제 및 이의 용도
MX2017010844A (es) 2015-02-24 2017-12-07 Pfizer Derivados de nucleosidos sustituidos utiles como agentes anticancerosos.
AU2017230658B2 (en) * 2016-03-10 2021-03-04 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
CA2969295A1 (en) 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
EP3939986A1 (en) * 2017-08-09 2022-01-19 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
IL318073A (en) 2019-03-25 2025-02-01 California Inst Of Techn PRMT5 inhibitors and their uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018528946A (ja) 2015-08-26 2018-10-04 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤として使用するための新規な６−６二環式芳香環置換ヌクレオシド類似体
WO2018065365A1 (en) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
WO2018160824A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2019110734A1 (en) 2017-12-08 2019-06-13 Janssen Pharmaceutica Nv Novel spirobicyclic analogues

Also Published As

Publication number Publication date
EP3947387B1 (en) 2024-10-23
MX2021011524A (es) 2021-12-15
CN114127072A (zh) 2022-03-01
US20220194949A1 (en) 2022-06-23
BR112021019125A2 (pt) 2021-11-30
IL318073A (en) 2025-02-01
CN114127072B (zh) 2024-10-11
KR20220023330A (ko) 2022-03-02
EP3947387A4 (en) 2022-11-30
WO2020198323A1 (en) 2020-10-01
SG11202110272SA (en) 2021-10-28
JP2022521818A (ja) 2022-04-12
AU2020245480A1 (en) 2021-11-11
US12583859B2 (en) 2026-03-24
CA3134779A1 (en) 2020-10-01
EP3947387A1 (en) 2022-02-09
IL286622A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
JP7609798B2 (ja) Ｐｒｍｔ５インヒビター及びその使用
CN116096372B (zh) 一种egfr抑制剂、其制备方法和在药学上的应用
TWI891621B (zh) 一種噠嗪類衍生物抑制劑、其製備方法和應用
JP7007302B2 (ja) メニン－ｍｌｌ相互作用の阻害剤
JP6893501B2 (ja) スルフィニルフェニル又はスルホンイミドイルフェニルベンザゼピン
EP3749646B1 (en) Heteroaryl compounds as kinase inhibitor
KR20090040923A (ko) Ｂｃｌ 단백질과 결합 파트너의 상호작용을 억제하기 위한 화합물 및 방법
JP2021506793A (ja) Ｐｒｍｔ５阻害剤としての置換二環式複素環式化合物
JP6966425B2 (ja) 抗がん剤としての複素環式の限定された三環系スルホンアミド
EP2903979B1 (en) Novel compounds, their preparation and their uses
CN105837586B (zh) 二噁烷并喹唑啉胺类化合物及其制备方法和作为表皮生长因子受体抑制剂的应用
CN106132968B (zh) 一种用于防止或治疗癌症的抑制溴结构域的化合物及含有该化合物的药物组合物
WO2020221209A1 (zh) 一种cd73抑制剂，其制备方法和应用
CN111094314B (zh) 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用
WO2020259703A1 (zh) 一种吡唑酮并嘧啶类化合物、其制备方法及应用
WO2023030335A1 (zh) 作为tyk2/jak1假激酶结构域抑制剂的化合物及合成和使用方法
HK40063243A (en) Prmt5 inhibitors and uses thereof
HK40063243B (en) Prmt5 inhibitors and uses thereof
WO2021067827A1 (en) Mcl1 inhibitors and uses thereof
KR101804449B1 (ko) 아이코티닙의 다형체 형태 및 이의 용도
WO2022216946A1 (en) Mcl1 inhibitors and uses thereof
CA2886744C (en) Imatinib derivatives, their preparation and use to treat cancer and bacterial and viral infections
WO2022162028A1 (en) Heteroaromatic phosphonium salts and their use treating cancer
CN118561872A (zh) 嘧啶并吡啶类生物抑制剂、其制备方法和应用
HK40052933A (en) Cd73 inhibitor, preparation method therefor and application thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230324

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240905

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241219

R150 Certificate of patent or registration of utility model

Ref document number: 7609798

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150